

Special Issue

Radioligand Therapy (RLT) in Neuroendocrine Neoplasms

Message from the Guest Editor

The treatment methods for neuroendocrine neoplasms (NENs) have been rapidly advancing in recent years. New treatment models now include the use of radioligand therapy (RLT) as an earlier line of treatment. The use of radiopharmaceuticals introduces new possibilities for patients, extending their progression-free survival and overall survival compared to other therapies. In light of this, we would like to extend an invitation to all researchers working in the field of neuroendocrine neoplasms and radioligand therapies to contribute to a Special Issue of *Cancers* entitled "Radioligand Therapy (RLT) in Neuroendocrine Neoplasms". We hope that you will share your experiences and study results with us. In addition to original articles, comprehensive reviews are also welcomed. We anticipate that the deadline of 31 October 2024, will be acceptable for all contributors and provide sufficient time for the preparation of high-value publications.

Guest Editor

Prof. Dr. Grzegorz Kamiński

Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, Szaserów 128, 04-141 Warsaw, Poland

Deadline for manuscript submissions

closed (15 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/192979

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)